Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a Canada-based patient-driven medical device company that provides healthcare solutions for advanced wound care, infection control, and medical device coatings. The Company's solutions are designed for patients and made for care providers. The Company leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon's name, and by developing and commercializing medical products for other medical companies under development and license contracts. The Company has three proprietary platform technologies that have the potential to be developed into a number of medical devices and products: Collagen matrix, Antimicrobial silicone adhesive and Medical coatings. Its product type includes advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, and perioperative dressings. Its brands include ColActive PLUS, CovaClear, CovaView, CovaWound, IV Clear, SurgiClear, and VALGuard.


TSXV:COV - Post by User

Bullboard Posts
Post by TheMonolithon Jul 22, 2019 2:11pm
109 Views
Post# 29947586

Lack of EPS

Lack of EPSThis seems to be a hangup for a contingent of shareholders.  While I would love to see more EPS, it's not what I personally am focused on for Covalon.  It takes a great deal of resources to build out the framework and infrastructure.  They have many high margin deals that could hit with new SKUs and divisions.  Once they have a much more established sales distribution network in the US and and Europe, EPS can become more of a foucs.  

I'm happy to watch them grow the business as the priority, and if they can come close to breakeven, that's fine by me.  

Licensing deals were alluded to in the last CC, and that will be the rocket sauce a shareholder should keep their eyes open for.  
Bullboard Posts